Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.7K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.7K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

7.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and Validation of the Moral Courage in Bullying Scale in Adolescents.

Journal of interpersonal violence·2026
Same author

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Cell reports. Medicine·2026
Same author

Newly identified invasion drivers define the tumor front in oral squamous cell carcinoma.

Cell death discovery·2026
Same author

GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma.

Cancer research·2026
Same author

The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.

The oncologist·2026
Same author

CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.

Scientific reports·2026

Related Experiment Video

Updated: Mar 8, 2026

Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR
10:34

Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR

Published on: February 1, 2013

14.7K

A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer.

Cristian Suárez-Cabrera1,2, Rita M Quintana1, Ana Bravo3

  • 1Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)/CIBERONC, Madrid, Spain.

Cancer Research
|January 22, 2017
PubMed
Summary

RAS pathway alterations are common in basal breast cancer. Loss of RAS GTPase-activating protein 1 (RASA1) contributes to malignant phenotypes, particularly in tumors with mutated p53.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.1K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K

Related Experiment Videos

Last Updated: Mar 8, 2026

Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR
10:34

Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR

Published on: February 1, 2013

14.7K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.1K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • RAS pathway mutations are prevalent in human cancers but infrequent in breast cancer.
  • RAS GTPase-activating proteins (RASGAPs) negatively regulate RAS signaling.
  • RAS pathway dysregulation is implicated in tumorigenesis.

Purpose of the Study:

  • To investigate the role of RAS pathway negative regulators in breast cancer development.
  • To explore the potential involvement of RASGAP genes, neurofibromin1 (Nf1) and RAS p21 protein activator (Rasa1), in mammary tumorigenesis.

Main Methods:

  • Generated mammary tumors in a mouse model using a mutagenic transposon system in a p53 heterozygous background.
  • Analyzed transposon insertion sites in tumor DNA.
  • Performed immunohistochemical analysis on human breast tumors and bioinformatic analysis of The Cancer Genome Atlas (TCGA) data.
  • Inactivated RASA1 in MCF10A cells to assess its effect on cellular phenotype.

Main Results:

  • Mammary tumors in the mouse model frequently exhibited transposon insertions in Nf1 and Rasa1.
  • Low RASA1 expression was common in human basal (triple-negative) and estrogen receptor-negative breast tumors.
  • Bioinformatic analysis revealed frequent RASA1 allelic loss, especially in basal tumors and in conjunction with TP53 mutations.
  • RASA1 inactivation in MCF10A cells induced a malignant phenotype in the presence of mutated p53.

Conclusions:

  • Loss of negative RAS regulators, specifically RASA1, may be a frequent event in basal breast cancer.
  • Alterations in the Ras pathway due to RASA1 inactivation contribute to malignant transformation in breast cancer.
  • RASA1 deficiency represents a potential therapeutic target in a subset of breast cancers.